Vialwirebiotech, curated
October 2, 2026, 3:49 AM
June 17, 2026
- 12:11 PM · Bloomberg — Technology12:11 PMBioNTech Investor Förtsch Says Founders’ Spinout Raises Concerns — Bloomberg — Technology
- 12:00 PM · Drug Discovery World12:00 PMTherapy enables 89% survival rate in myeloma patients — Drug Discovery World
- 12:00 PM · BioWorld12:00 PMSpyre’s Skyline-UC double win lifts hopes for IBD antibody combos — BioWorld
- 12:00 PM · BioWorld12:00 PMHMNC raises $50M series B to prep depression drugs for phase III — BioWorld
- 12:00 PM · BioWorld12:00 PMRx tariff just around the corner — BioWorld
- 11:30 AM · Drug Discovery World11:30 AMUlcerative colitis treatment shows best-in-class potential — Drug Discovery World
- 11:09 AM · BioPharma Dive11:09 AMJazz zeroes in on next-gen T cell engagers with AbCellera deal — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMAcumen selects development candidates for Alzheimer’s disease — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMCalidi receives pre-IND feedback from FDA on CLD-401 — BioWorld
- 9:00 AM · BioWorld9:00 AMVedana Therapeutics launches with focus on migraine — BioWorld
- 8:30 AM · SCMP — Tech8:30 AMChinese chip-equipment maker CFMEE targets US$410 million in Hong Kong IPO — SCMP — Tech
- 7:43 AM · STAT News
- 6:17 AM · Pharmaceutical Technology6:17 AMAviadoBio broadens vMiX gene silencing licence with King’s College London — Pharmaceutical Technology
- 5:32 AM · Pharmaceutical Technology5:32 AMEHA26: BMS touts positive multiple myeloma data for two pipeline candidates — Pharmaceutical Technology
- 5:00 AM · BioPharma Dive5:00 AMA new Westlake-backed biotech takes aim at migraines — BioPharma Dive
- 4:56 AM · Pharmaceutical Technology4:56 AMAltaris to acquire Simulations Plus in $375m all-cash deal — Pharmaceutical Technology
- 4:53 AM · Pharmaceutical Technology4:53 AMZai Lab’s zocilurtatug pelitecan secures EMA orphan drug status — Pharmaceutical Technology
June 16, 2026
- 12:23 PM · BioPharma Dive12:23 PMLilly buys non-opioid pain drugmaker 4E — BioPharma Dive
- 12:00 PM · BioWorld12:00 PM2025 annual report reflects the changing role of EMA — BioWorld
- 12:00 PM · BioWorld12:00 PMOricell brings first pivotal-stage CAR T in liver cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMChinese challenger Gan & Lee gains momentum in metabolic disease — BioWorld
- 12:00 PM · BioWorld12:00 PMEdgewise heads to phase III with solid EDG-7500 data in HCM — BioWorld
- 12:00 PM · BioWorld12:00 PMThree deals in six days: Everest builds late-stage APAC portfolio — BioWorld
- 12:00 PM · BioWorld12:00 PMTakeda’s zasocitinib bests Sotyktu in phase III psoriasis trial — BioWorld
- 12:00 PM · BioWorld12:00 PMChina clears Alphamab’s HER2 bispecific antibody in gastric cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMLaekna licenses LAE-118 ex-China to Vasque in $527M deal — BioWorld
- 12:00 PM · BioWorld12:00 PMElixiron’s enrupatinib shows upbeat interim phase II AD results — BioWorld
- 12:00 PM · BioWorld12:00 PMLongbio’s LP-003 meets phase III allergy endpoints — BioWorld
- 9:15 AM · PharmaVoice9:15 AMHow Lilly is defending its GLP empire — PharmaVoice
- 9:08 AM · BioPharma Dive9:08 AMNeumora depression drug fails; EnGene to cut 50% of staff — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMImmunomic’s ITI-9001 to enter clinic for Japanese red cedar allergy — BioWorld
- 9:00 AM · BioWorld9:00 AMTechnophage’s bacteriophage cocktail cleared for clinic — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMAvalo Therapeutics advances AVTX-010 for hidradenitis suppurativa — BioWorld
- 8:07 AM · SCMP — Tech8:07 AMHong Kong Science Park, SenseTime partner to build home-grown AI data centre — SCMP — Tech
- 8:00 AM · Drug Discovery World8:00 AMVertex presents new data on Casgevy in children — Drug Discovery World
- 8:00 AM · STAT News
- 7:31 AM · Pharmaceutical Technology7:31 AMCystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug — Pharmaceutical Technology
- 6:38 AM · Pharmaceutical Technology6:38 AMEHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML — Pharmaceutical Technology
- 6:04 AM · Pharmaceutical Technology6:04 AMAlkermes’ alixorexton secures FDA and EC orphan designations — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMA potentially practice-changing advance in bile duct cancer — Drug Discovery World
- 4:42 AM · Pharmaceutical Technology4:42 AMALK’s EURneffy secures MHRA approval for anaphylaxis treatment — Pharmaceutical Technology